Healthcare Industry News: Healthpoint
News Release - October 24, 2006
Onset Therapeutics Features Three Scientific Posters at ASWC on Recently Launched OPTASE(TM), a Novel Wound Care GelCUMBERLAND, R.I.--(HSMN NewsFeed)--Onset Therapeutics, a specialty pharmaceutical company focused on the development and commercialization of innovative, patent protected topical products for the treatment of skin and wound related disorders, announced today that OPTASE(TM) GEL was featured in three scientific posters at the Clinical Symposium on Advances in Skin and Wound Care (ASWC) held September 28-30, 2006 in Lake Buena Vista, FL.
OPTASE(TM) GEL (Trypsin, Balsam Peru, Castor Oil) is a wound care product formulated in a patent pending Gel delivery system for topical application on a wide variety of wounds. It is indicated to promote healing and the treatment of pressure ulcers, venous and arterial ulcers and dehiscent wounds. OPTASE(TM) Gel was developed by a team of scientists to specifically address some of the limitations inherent in currently available wound care formulations.
Kimberly Miner ND, CNS, CWCN, FAPWCA presented a poster entitled "Treatment of Stage I and II Pressure Ulcers with a Novel Balsam Peru, Castor Oil and Trypsin Formulation" that described a case study in which OPTASE(TM) GEL was used to successfully treat a recurrent stage II pressure ulcer that had failed to respond to previous wound treatments in a home based care setting.
Mark W. Trumbore Ph.D presented a poster entitled "The Ability of Two BCT Wound Treatments to Prevent Transepidermal Water-loss (TEWL) and Wound Contamination". This poster detailed the results of a clinical study and a series of in vitro models comparing the effectiveness of two different formulations of Balsam Peru, Castor Oil, Trypsin (BCT) wound treatments, OPTASE(TM) GEL and XENADERM® OINTMENT (Healthpoint LTD) to act as a barrier to TEWL, as well as a barrier to external contaminants that were introduced to the in vitro models.
Mark W. Trumbore Ph.D also presented a poster entitled "Development of a Rodent Model for Evaluating BCT Wound Treatment Efficacy" that described the development and use of a rodent wound model for comparing the efficacy of BCT wound care treatments. The study compared the healing of wounds treated with either OPTASE(TM) GEL, GRANULEX® SPRAY (Mylan Bertek), XENADERM® OINTMENT or saline.
"In addition to focusing our product development efforts to meet unmet market needs and improving upon currently available therapies, we are committed to providing, evidence based data that supports the differentiation of our products", states Michael Heffernan R.Ph., President of Onset Therapeutics. "Our goal is to develop products that provide optimized delivery and performance while striving to improve the quality of life of patients using our products."
Development and commercialization of novel therapies with clinical enhancements over existing products in the market is the core of Onset's strategy. Onset Therapeutics expects to launch several additional wound care products over the next year, in addition to numerous dermatology products incorporating the company's novel Foam Vehicle Technology.
About Onset Therapeutics
Onset Therapeutics is a privately held specialty pharmaceutical company focusing on the development and commercialization of novel, patent protected topical products for the treatment of wounds and skin disorders. For more information, please visit the company's website at www.onsettx.com
Source: Onset Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.